Sanofi: extraordinary charge in Q4.
(CercleFinance.com) - After trading on Wednesday Sanofi announced that it will ask the health authorities to update information provided to doctors and patients about its vaccine against dengue, Dengvaxia, in countries where it has been approved.
This request has been motivated by a new analysis of the long-term results of clinical studies of the vaccine, which have showed differences in performance based on past dengue infections. The said analysis, which took 6 years, confirmed that Dengvaxia provides a persistent protective effect against dengue in people already infected in the past.
Regarding people with no history of dengue, the analyses revealed that over the longer term, following vaccination, more severe cases of dengue could be seen in case of exposure to the virus.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
This request has been motivated by a new analysis of the long-term results of clinical studies of the vaccine, which have showed differences in performance based on past dengue infections. The said analysis, which took 6 years, confirmed that Dengvaxia provides a persistent protective effect against dengue in people already infected in the past.
Regarding people with no history of dengue, the analyses revealed that over the longer term, following vaccination, more severe cases of dengue could be seen in case of exposure to the virus.
Copyright (c) 2017 CercleFinance.com. All rights reserved.